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Abstract
Background:  R122, the primary autolysis site of the human cationic trypsinogen (PRSS1),
constitutes an important "self-destruct" or "fail-safe" defensive mechanism against premature
trypsin activation within the pancreas. Disruption of this site by a missense mutation, R122H, was
found to cause hereditary pancreatitis. In addition to a c.365G>A (CGC>CAC) single nucleotide
substitution, a c.365~366GC>AT (CGC>CAT) gene conversion event in exon 3 of PRSS1 was also
found to result in a R122H mutation. This imposes a serious concern on the genotyping of
pancreatitis by a widely used polymerase chain reaction-restriction fragment length polymorphism
assay, which could only detect the commonest c.365G>A variant.
Materials and methods: DNA samples containing either the known c.365G>A or
c.365~366GC>AT variant in exon 3 of PRSS1 were used as positive controls to establish a
denaturing high performance liquid chromatography (DHPLC) assay.
Results: DHPLC could readily discriminate the two known different mutational events resulting in
the R122H mutation. More importantly, under the same experimental conditions, it identified a
further mutational event that also occurs in the R122 primary autolysis site but results in a different
amino acid substitution: c.364C>T (CGC>TGC; R122C).
Conclusions: A rapid, simple, and low-cost assay for detecting both the known and new mutations
occuring in the R122 primary autolysis site of PRSS1 was established. In addition, the newly found
R122C variant represents a likely pancreatitis-predisposing mutation.
Background
Trypsin plays a central role in pancreatic exocrine phys-
iology by acting as the trigger enzyme that leads to the
activation of all the digestive proenzymes. To prevent
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premature trypsin activation within the pancreas, the
body has evolved a series of defensive mechanisms. Of
particular significance is the "built-in" R122 primary au-
tolysis site of mammalian trypsinogens, which serves as
a "self-destruct" or "fail-safe" mechanism to prevent
pancreatic autodigestion [1]. Disruption of this site by a
missense mutation – R122H (originally termed R117H in
the chymotrypsin numbering system [2]; for a discussion
of mutation nomenclature see [3,4]) – in the human cat-
ionic trypsinogen (PRSS1; OMIM 276000) has been as-
sociated with most of the large kindreds with hereditary
pancreatitis (HP; OMIM 167800) [1].
The initially identified R122H mutation results from a
c.365G>A (CGC>CAC) transition in exon 3 of PRSS1[2].
Since this mutation creates a novel restriction recogni-
tion site for Alf III (A↓ CRYGT), a polymerase chain reac-
tion-restriction fragment length polymorphism (PCR-
RFLP) assay was established [2] and has been widely ap-
dopted to detect this most frequent mutation in both he-
reditary and sporadic cases of pancreatitis [summarized
in [5]]. However, this simple assay fails to detect a
c.365~366GC>AT (CGC>CAT) gene conversion event
that also results in a R122H mutation [6]. The latter was
first identified in a sporadic chronic pancreatitis subject
by denaturing gradient gel electrophoresis (DGGE) [5]
and confirmed in a HP family by direct sequencing [7].
Here we undertook to establish a new technique – dena-
turing high-performance liquid chromatography (DH-
PLC) – for accurately genotyping the two different
mutational events resulting in the R122H mutation.
Moreover, we identified a further mutational event that
appears also to disrupt the R122 primary autolysis site of
PRSS1.
Results and discussion
For genotyping known genetic variants, PCR-RFLP, if
available, represents the most simple and rapid method.
However, it has an intrinsic disadvantage, that is, it could
only detect a "specific" variant, exemplified by the PCR-
RFLP analysis of the c.365G>A (CGC>CAC; R122H) var-
iant in PRSS1[2]. DGGE is one of the most powerful tech-
niques for mutation detection and screening but,
unfortunately, it is time-consuming and technically diffi-
cult to implement [5].
DHPLC is an automated technology for mutation screen-
ing based on the separation of heteroduplexes from ho-
moduplexes on a stationary phase under partialy
denaturing conditions [8]. This technique was initially
used for identifying single nucleotide polymorphisms on
the Y chromosome [9] and, thereafter, has been emerg-
ing as a sensitive, rapid, low-cost, and reliable method
for mutation detection and screening in different genes,
including the cystic fibrosis transmembrane conduct-
ance regulator gene [10], the hereditary hemochromato-
sis gene [11], and the BRCA1 and BRCA2 genes [12].
In this report, DHPLC was attempted to screen the two
known mutational events in exon 3 of PRSS1 that result
in the most frequent pancreatitis-associated R122H mu-
tation. As shown in Fig 1, this technique could readily
discriminate the two different mutational events in all of
our positive control samples. Moreover, it identified new
c.365G>A (CGC>CAC; R122H) carriers in our cohort of
chronic pancreatitis subjects (data not shown). Further,
it found a novel autolysis site mutation: a c.364C>T
(CGC>TGC) transition, which is presumed to result in a
Figure 1
Detection of three mutational events in exon 3 of PRSS1
resulting in a disruption of the R122 primary autolysis site of
human cationic trypsinogen. Left panel: denaturing high
performance liquid chromatography (DHPLC) profile of the
mutant compared with the wild type sequence. Right panel:
direct DNA sequencing of independently amplified polymer-
ase chain reaction products. Mutations are indicated by
arrows.  A: c.365G>A(CGC>CAC; R122H); B:
c.365~366GC>AT (CGC>CAT; R122H); C: c.364C>T
(CGC>TGC; R122C). Refer to Table 1 for a summary of
these mutational events.
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R122C amino acid change of the human cationic
trypsinogen (Fig. 1), was detected in a 42 years old wom-
en with idiopathic chronic pancreatitis. This new variant
was not present in 300 French healthy blood donors
evaluated by DHPLC. To date, this c.364C>T
(CGC>TGC) variant and the c.365~366GC>AT
(CGC>CAT) variant have only been detected once each
in our cohort of about 400 French patients with chronic
pancreatitis.
Here it might be interersting to note that while the
c.365G>A (CGC>CAC; R122H) could be attributable to a
spontaneous deamination of 5-methylcytosine to give
thymine in the CpG island on the antisense strand, the
c.364C>T (CGC>TGC; R122C) could be attributable to
such an event on the sense strand. Thus the R122 prima-
ry autolysis site seems to be particularly susceptible to
mutational events (CpG island and gene conversion-pro-
moting structure) despite of a strong selection pressure
(Table 1). Nevertheless, the nature of the R122C variant
suggests that it is a likely pancreatitis-predisposing mu-
tation: an arginine to cysteine substitution is expected to
disrupt the R122 primary autolysis site simply because
cysteine could not be cleaved by trypsin, as in the case of
the R122H mutation. However, the resistance to autoly-
sis confered by the R122C mutation may be somehow dif-
ferent from that confered by the R122H mutation in a
quantitative manner. In parallel functional analysis of
the R122H and R122C mutations would certainly help
determine genotype/phenotype correlation.
Conclusions
This study, for the first time, established a new technique
– DHPLC – for genotying the different mutational events
occuring in the R122 primary autolysis site of PRSS1. Im-
portantly, this technique could not only discriminate the
two known mutational events, but also identified a fur-
ther mutational event that occurs in the R122 primary
autolysis site of PRSS1. Thus this assay avoids the pitfall
of the existing PCR-RFLP method. Moreover, it is more
easily performed compared with the DGGE technique.
Finally, the newly found R122C variant represents a like-
ly pancreatitis-predisposing mutation.
Materials and methods
Samples
DNA was isolated from blood cells by salt precipitation
method from chronic pancratitis subjects. DNA samples
with the known c.365G>A (CGC>CAC; R122H) or
c.365~366GC>AT (CGC>CAT; R122H) mutations in
exon 3 of PRSS1 were used as positive controls.
Amplification of exon 3 of PRSS1
Primers' sequences used for PCR amplification of exon 3
of PRSS1 were TCCATgAgCAgAgAgCTTgAggAA (sense)
and TgTgAggATggAgggAAgTAgAAggACT (antisense).
PCR was performed in 50 µ l reaction volume using am-
pliTaq DNA Polymerase (Perkin Elmer). Particularly,
Touchdown PCR protocol [13] was used and cycling con-
ditions were as follows: denaturation step at 94°C for 3
min; 14 touchdown cycles with decreasing 0,5°C anneal-
ing temperature per cycle from 70 to 63°C (denaturation
94°C for 20 sec, annealing for 40 sec, primer extension
72°C for 45 sec); 25 cycles at 63 °C annealing tempera-
ture, final elongation step at 72°C for 7 min; heterodu-
plexes formation by denaturing at 95°C and cooling by
1°C step per minute through 65°C in 30 minutes. All re-
actions were carried out using GeneAmp®PCR system
9700 (Perkin Elmer).
DHPLC analysis
DHPLC was performed using the Transgenomic WAVE®
system as described by Kuklin et al.[9]. 5 µl of crude PCR
samples were loaded to a preheated C18 reverse-phase
column based on non-porous poly(styrene-divinyl ben-
zene) particles (DNASep column Transgenomic™). DNA
(homo +/- heteroduplexes) was eluted from the column
by a linear acetonitrile gradient in 0,1 mM Triethylamine
acetate buffer (TEAA) (Transgenomic), pH 7 at a con-
stant flow rate of 0,9 ml/mn. Gradient was formed by
mixing buffer A (0,1 mM TEAA) and buffer B (0,1 mM
TEAA, 25% acetonitrile). Analysis gradient lasted 2,5 mn
with buffer B increasing from 55 to 60%. Then the col-
umn was cleaned by 100 % buffer B for 0,5 minute and
equilibrated with start condition for 2 minutes before
next injection. Elution of DNA was detected by 260 nm
UV absorbance. The temperature of the oven was fixed to
Table 1: The three different mutational events resulting in a disruption of the R122 primary autolysis site of the human cationic 
trypsinogen
cDNA change(s) Location Codon change Amino acid change Designation Comments Reference(s)
c.365G>A Exon3 CGC>CAC Arg>His at 122 R122H At CpG (antisense strand) 2,6
C.365~366GC>AT Exon3 CGC>CAT Arg>His at 122 R122H Gene conversion 5,6
C.364C>T Exon3 CGC>TGC Arg>Cys at 122 R122C At CpG (sense strand) This studyBMC Genetics 2001, 2:19 http://www.biomedcentral.com/1471-2156/2/19
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64°C after evaluation with software melting simulation
(Wavemaker 4.1). HSM® software regulated every pa-
rameter of Wave® system during analysis and stored da-
ta.
Direct DNA sequencing
Direct DNA sequencing was performed using the ABI
PRISM™ BigDye™ Terminator Cycle Sequencing Kit
(PE Applied Biosystems, Foster City, CA) with the same
PCR primers on an ABI 310 sequencer.
Note added in proof
Note added in proof: The R122C mutation was independ-
ently reported by Simon P, Weiss FU, Sahin-Toth M,
Parry M, Nayler O, Lenfers B, Schnekenburger J, Mayer-
le J, Domschke W, Lerch MM. Hereditary pancreatitis
caused by a novel PRSS1 mutation (Arg-122uCys) that al-
ters autoactivation and autograduation of cationic
trypsinogen. J Bio Chem. 2001 [epub ahead of print]
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